 ESSA Pharma Inc. ESSA, or the Company Nasdaq: EPIX, TSX-V: EPI, a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM the ATM Sales Agreement with Jefferies LLC, effective as of April 13, 2020. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US35.0 million in aggregate sales proceeds in at-the-market transactions. No offers or sales of common shares will be made in Canada, to anyone known by Jefferies, LLC to be a resident of Canada or on or through the facilities of the TSX Venture Exchange TSXV or other trading markets in Canada. 